Table 4.
First strategy: intravenous administration | BM-MSCs are transfused into the left ventricular cavity. Stem cells mainly reach the lungs, with significantly smaller amounts in the liver, heart, and spleen. | [52] |
| ||
Second strategy: intracoronary infusion | Patients are infused with BM-progenitor cells using a balloon catheter after restoration of arterial patency | [53–55] |
| ||
Third strategy: Transepicardial administration | Direct transepicardial injection of BMSCs can be performed, using a surgical thoracotomy into the border zone of the infarct | [59] |
| ||
Third strategy: transendocardial administration | Catheter-based transendocardial injection of SCs using electromechanical voltage mapping to define tissue viability | [59] |